259 related articles for article (PubMed ID: 17048487)
1. Design and characterisation of poly(lactide-co-glycolide) small particulate systems for the delivery of immunostimulant CpG oligonucleotide.
Shakweh M; Fattal E
J Nanosci Nanotechnol; 2006; 6(9-10):2811-20. PubMed ID: 17048487
[TBL] [Abstract][Full Text] [Related]
2. Poly(lactide-co-glycolide) microspheres for the controlled release of oligonucleotide/polyethylenimine complexes.
De Rosa G; Quaglia F; La Rotonda MI; Appel M; Alphandary H; Fattal E
J Pharm Sci; 2002 Mar; 91(3):790-9. PubMed ID: 11920765
[TBL] [Abstract][Full Text] [Related]
3. Influence of formulation parameters on the characteristics of poly(D, L-lactide-co-glycolide) microspheres containing poly(L-lysine) complexed plasmid DNA.
Capan Y; Woo BH; Gebrekidan S; Ahmed S; DeLuca PP
J Control Release; 1999 Aug; 60(2-3):279-86. PubMed ID: 10425333
[TBL] [Abstract][Full Text] [Related]
4. Controlled release of NFkappaB decoy oligonucleotides from biodegradable polymer microparticles.
Zhu X; Lu L; Currier BL; Windebank AJ; Yaszemski MJ
Biomaterials; 2002 Jul; 23(13):2683-92. PubMed ID: 12059017
[TBL] [Abstract][Full Text] [Related]
5. Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake.
Sahoo SK; Panyam J; Prabha S; Labhasetwar V
J Control Release; 2002 Jul; 82(1):105-14. PubMed ID: 12106981
[TBL] [Abstract][Full Text] [Related]
6. Rational design, fabrication, characterization and in vitro testing of biodegradable microparticles that generate targeted and sustained transgene expression in HepG2 liver cells.
Intra J; Salem AK
J Drug Target; 2011 Jul; 19(6):393-408. PubMed ID: 20681752
[TBL] [Abstract][Full Text] [Related]
7. Immunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN.
Tafaghodi M; Khamesipour A; Jaafari MR
Parasitol Res; 2011 May; 108(5):1265-73. PubMed ID: 21125294
[TBL] [Abstract][Full Text] [Related]
8. Nimodipine loaded PLGA nanoparticles: formulation optimization using factorial design, characterization and in vitro evaluation.
Mehta AK; Yadav KS; Sawant KK
Curr Drug Deliv; 2007 Jul; 4(3):185-93. PubMed ID: 17627492
[TBL] [Abstract][Full Text] [Related]
9. A new delivery system for antisense therapy: PLGA microspheres encapsulating oligonucleotide/polyethyleneimine solid complexes.
De Rosa G; Bochot A; Quaglia F; Besnard M; Fattal E
Int J Pharm; 2003 Mar; 254(1):89-93. PubMed ID: 12615416
[TBL] [Abstract][Full Text] [Related]
10. Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano- and microparticles.
Panyam J; Dali MM; Sahoo SK; Ma W; Chakravarthi SS; Amidon GL; Levy RJ; Labhasetwar V
J Control Release; 2003 Sep; 92(1-2):173-87. PubMed ID: 14499195
[TBL] [Abstract][Full Text] [Related]
11. Preparation and characterization of cationic PLGA nanospheres as DNA carriers.
Ravi Kumar MN; Bakowsky U; Lehr CM
Biomaterials; 2004 May; 25(10):1771-7. PubMed ID: 14738840
[TBL] [Abstract][Full Text] [Related]
12. Development of a poly (lactic-co-glycolic acid) particle vaccine to protect against house dust mite induced allergy.
Joshi VB; Adamcakova-Dodd A; Jing X; Wongrakpanich A; Gibson-Corley KN; Thorne PS; Salem AK
AAPS J; 2014 Sep; 16(5):975-85. PubMed ID: 24981892
[TBL] [Abstract][Full Text] [Related]
13. Development and in vitro evaluation of surface modified poly(lactide-co-glycolide) nanoparticles with chitosan-4-thiobutylamidine.
Grabovac V; Bernkop-Schnürch A
Drug Dev Ind Pharm; 2007 Jul; 33(7):767-74. PubMed ID: 17654025
[TBL] [Abstract][Full Text] [Related]
14. Incorporation and in vitro release of doxorubicin in thermally sensitive micelles made from poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide)-b-poly(D,L-lactide-co-glycolide) with varying compositions.
Liu SQ; Tong YW; Yang YY
Biomaterials; 2005 Aug; 26(24):5064-74. PubMed ID: 15769542
[TBL] [Abstract][Full Text] [Related]
15. Novel polymer-DNA hybrid polymeric micelles composed of hydrophobic poly(D,L-lactic-co-glycolic acid) and hydrophilic oligonucleotides.
Jeong JH; Park TG
Bioconjug Chem; 2001; 12(6):917-23. PubMed ID: 11716682
[TBL] [Abstract][Full Text] [Related]
16. Preparation and characterization of PLGA nanospheres for the targeted delivery of NR2B-specific antisense oligonucleotides to the NMDA receptors in the brain.
Kilic AC; Capan Y; Vural I; Gursoy RN; Dalkara T; Cuine A; Hincal AA
J Microencapsul; 2005 Sep; 22(6):633-41. PubMed ID: 16401579
[TBL] [Abstract][Full Text] [Related]
17. Oral nuclear factor-κB decoy oligonucleotides delivery system with chitosan modified poly(D,L-lactide-co-glycolide) nanospheres for inflammatory bowel disease.
Tahara K; Samura S; Tsuji K; Yamamoto H; Tsukada Y; Bando Y; Tsujimoto H; Morishita R; Kawashima Y
Biomaterials; 2011 Jan; 32(3):870-8. PubMed ID: 20934748
[TBL] [Abstract][Full Text] [Related]
18. Biodegradable microparticles for the controlled delivery of oligonucleotides.
De Rosa G; Quaglia F; La Rotonda M; Besnard M; Fattal E
Int J Pharm; 2002 Aug; 242(1-2):225-8. PubMed ID: 12176251
[TBL] [Abstract][Full Text] [Related]
19. Design and development of a novel controlled release PLGA alginate-pectinate polyspheric drug delivery system.
Sweet JL; Pillay V; Choonara YE
Drug Deliv; 2007 Jul; 14(5):309-18. PubMed ID: 17613019
[TBL] [Abstract][Full Text] [Related]
20. Preparation and characterization of poly-(D,L-lactide-co-glycolide) and poly-(L-lactic acid) microspheres with entrapped pneumotropic bacterial antigens.
Kofler N; Ruedl C; Klima J; Recheis H; Böck G; Wick G; Wolf H
J Immunol Methods; 1996 Jun; 192(1-2):25-35. PubMed ID: 8699019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
